BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2680 related articles for article (PubMed ID: 12615723)

  • 1. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
    Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
    Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L; Fang B
    Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
    Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
    Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
    Hermisson M; Weller M
    Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
    Suliman A; Lam A; Datta R; Srivastava RK
    Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB; Bhardwaj U; Takada Y
    Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
    Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
    Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis.
    Kim HS; Chang I; Kim JY; Choi KH; Lee MS
    Cancer Res; 2005 Jul; 65(14):6111-9. PubMed ID: 16024612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
    Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
    J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines.
    Guseva NV; Taghiyev AF; Sturm MT; Rokhlin OW; Cohen MB
    Mol Cancer Res; 2004 Oct; 2(10):574-84. PubMed ID: 15498932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
    Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 134.